Three Hundred Missing Oxycodone Tablets: Loss Reporting and Investigation
During a month-end controlled substance reconciliation, the pharmacist-in-charge of a community pharmacy in Queens finds that 300 oxycodone 15 mg tablets are unaccounted for over the past six weeks. Purchase invoices show 1,200 tablets received; dispensing records show 700 dispensed; inventory shows 200 on hand. The expected balance was 500. A review of access logs shows that three technicians and two pharmacists had access to the safe; one technician was recently terminated for attendance issues. The pharmacy’s security camera footage is retained for 30 days. The pharmacist-in-charge is unsure whether to wait for the owner’s attorney, confront the staff, or notify anyone. The pharmacy holds a DEA registration and all required New York registrations. The owner is out of the country and has asked the pharmacist-in-charge to “handle it quietly” until the attorney returns next week.
1. What reports must be made, to whom, and on what timeline?
Read the worked answer
The pharmacist-in-charge must not wait a week to report a significant loss of a controlled substance. Federal law requires the pharmacy to notify the DEA of a theft or significant loss and to submit DEA Form 106 within one business day of discovery. New York also requires notification to the Department of Health, Bureau of Narcotic Enforcement, for theft or significant loss of controlled substances, and the pharmacy should follow the Bureau’s instructions for reporting and documentation. The owner and the pharmacy’s attorney should be informed, but attorney availability does not suspend the reporting deadline. If the investigation suggests employee theft, the pharmacy should also consult counsel about reporting to law enforcement and about any applicable licensure-board reporting. The pharmacist-in-charge should document the date and time the loss was discovered and the date and time each report was made.
2. What immediate steps should the pharmacist-in-charge take to investigate and preserve evidence?
Read the worked answer
The pharmacist-in-charge should secure the controlled substance records and the safe area, preserve the access logs, and preserve the camera footage before the 30-day retention period expires. The pharmacist-in-charge should perform a careful recount and reconcile purchases, dispensing records, returns, and waste records to determine whether the discrepancy is a true loss or a recordkeeping error. Staff should not be confronted in a way that could compromise an investigation or endanger anyone; interviews should be conducted with counsel or human resources, and the pharmacist-in-charge should avoid making accusations based on suspicion alone. All steps, including who reviewed what and when, should be documented. The pharmacist-in-charge should not alter or destroy records and should not create replacement records that make the inventory appear correct.
3. If a second recount shows 500 tablets on hand and the discrepancy was a recordkeeping error, what should the pharmacist-in-charge do?
Read the worked answer
If a verified recount and reconciliation show that the 500 tablets are actually present and that the apparent loss was caused by a recordkeeping error, the pharmacist-in-charge should correct the records and document the basis for the correction. The pharmacist-in-charge should determine whether any report already filed needs to be amended or explained to the DEA and the New York Bureau of Narcotic Enforcement. The pharmacist-in-charge should not simply delete the discrepancy; the correction should be traceable, with a clear explanation of what was counted, who counted it, and why the earlier figure was wrong. Even if there was no actual theft, the event reveals a recordkeeping weakness. The pharmacy should strengthen inventory reconciliation, access controls, and staff training, and the pharmacist-in-charge should document the corrective action. A false or premature report is not the goal; accurate reporting and accurate records are.